ArticleFrontiers in immunology2026
Case Report: Sequential FcRn blockade and B-cell depletion for treatment-refractory relapsing autoimmune encephalitis: a three-patient case series.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Refractory autoimmune encephalitis (AE), particularly in patients experiencing recurrent relapses, presents significant therapeutic challenges and underscores the urgent need for innovative treatment strategies. Emerging evidence shows efgartigimod (EFG) rapidly clears pathogenic antibodies (days), while rituximab (RTX) suppresses new antibody production (weeks-months). Their synergistic temporal effects provide a rationale for exploring sequential EFG-RTX as a treatment strategy. Here, we describe the preliminary clinical outcomes observed in three patients with refractory AE who received this sequential regimen. Case presentations: The cohort included three refractory cases: A 30-year-old female patient diagnosed with anti-glutamate decarboxylase 65 encephalitis, who had experienced three disease relapses and presented with refractory epilepsy, a 54-year-old female with relapsed anti-leucine-rich glioma-inactivated protein 1 encephalitis showing progressive cognitive decline and psychiatric symptoms, and a 19-year-old female with relapsed anti-N-methyl-D-aspartate receptor encephalitis, characterized by severe cognitive dysfunction, psychiatric disturbances, depressed consciousness, and central hypoventilation. All patients had demonstrated resistance to both first-line immunotherapies and second-line agents including cyclophosphamide. Notably, administration of EFG yielded substantial clinical improvement in all cases, with sustained remission achieved following subsequent RTX and no evidence of disease relapse. Conclusion: In this small case series, sequential EFG-RTX therapy was associated with substantial clinical improvement and sustained remission in three patients with highly refractory, relapsing AE. These preliminary observations suggest that this synergistic approach may represent a viable therapeutic option for similar difficult-to-treat cases and warrants further investigation in larger, controlled studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.